

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner,

v.

ASTRAZENECA AB,  
Patent Owner.

---

Case IPR2016-01316  
Patent 6,774,122 B2

---

Before BRIAN P. MURPHY, ZHENYU YANG, and  
ROBERT A. POLLOCK, *Administrative Patent Judges*.

MURPHY, *Administrative Patent Judge*.

DECISION  
Termination of the Proceeding  
*37 C.F.R. §§ 42.72, 42.74*

On January 9, 2017, the parties filed a Joint Motion to Terminate this proceeding pursuant to 35 U.S.C. § 317(a). Paper 11. In addition, pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), the parties filed a true and correct copy of a Settlement and License Agreement (Paper 12), along with a Joint Request That Settlement Agreement Be Treated as Business Confidential Information, to be kept separate from the publicly available patent files (Paper 13).

This case is in the preliminary stage. No decision on whether to institute a trial has been made. Under the circumstances, it is appropriate to terminate the proceeding. Therefore, the Joint Motion to Terminate this proceeding is GRANTED.

Accordingly, it is

ORDERED that the Joint Motion to Terminate Proceeding is GRANTED and the proceeding is hereby TERMINATED; and

FURTHER ORDERED that the Joint Request That Settlement Agreement Be Treated as Business Confidential Information is GRANTED, and the Settlement and License Agreement will be kept separate from the patent files.

Case IPR2016-01316  
Patent 6,774,122 B2

PETITIONER:

Brandon M. White  
Crystal R. Canterbury  
PERKINS COIE LLP  
BMWhite@PerkinsCoie.com  
CCanterbury@PerkinsCoie.com

PATENT OWNER:

Filko Prugo  
Caitlin Hogan  
Marc Pensabene  
John Murray  
O'MELVENY & MYERS LLP  
fprugo@omm.com  
chogan@omm.com  
mpensabene@omm.com  
kmurray2@omm.com